case_images: PMC10685759_01
case_images: The clinical course of the case 1.
case_images: 10.1177_17588359231216090-fig1.jpg
case_images: PMC10685759_01_10.1177_17588359231216090-fig1.jpg
case_images: fig1-17588359231216090
case_images: In addition to the aforementioned gene alterations, genetic analysis of primary tumor tissue using the OncoGuide  NCC Oncopanel System (Sysmex Corporation, Hyogo, Japan) revealed several oncogenic gene alterations (Figure 1).
case_images: (a) The CT scan before administration of irinotecan plus cetuximab and (b) After 2 months, a CT scan revealed the ascites had vanished (arrowhead).
case_images: 10.1177_17588359231216090-fig2.jpg
case_images: PMC10685759_01_10.1177_17588359231216090-fig2.jpg
case_images: fig2-17588359231216090
case_images: After 2 months, a CT scan revealed that the ascites had vanished [Figure 2(a) and (b)].
case_images: PMC10685759_02
case_images: The clinical course of the case 2.
case_images: 10.1177_17588359231216090-fig3.jpg
case_images: PMC10685759_02_10.1177_17588359231216090-fig3.jpg
case_images: fig3-17588359231216090
case_images: It revealed several actionable genomic alterations and a high tumor mutation burden, but not the KRAS G12D mutation (Figure 3).
case_images: (a) The CT scan before administration of cetuximab monotherapy and (b) After 3 months, a CT scan revealed remarkable shrinkage of the liver metastasis (arrowhead).
case_images: 10.1177_17588359231216090-fig4.jpg
case_images: PMC10685759_02_10.1177_17588359231216090-fig4.jpg
case_images: fig4-17588359231216090
case_images: After 3 months, a CT scan revealed remarkable shrinkage of the liver metastasis [Figure 4(a) and (b)].